Navigation Links
The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia

Free, Interactive Workshop Features CML Expert, Jorge Cortes, M.D.

WHITE PLAINS, N.Y., Sept. 6 /PRNewswire/ -- Jorge Cortes, M.D., an expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled CML: A Model in Cancer Therapy. The program is scheduled for Thursday, Sept. 20, 2007, 12:00 p.m. - 1:00 p.m. ET.

The program is being offered by The Leukemia & Lymphoma Society, the leading source of information and support for patients battling leukemia, lymphoma and myeloma, and is supported by an unrestricted educational grant from Novartis.

Dr. Cortes is the deputy chair for the department of leukemia and professor of medicine and internist at The University of Texas M.D. Anderson Cancer Center in Houston, TX. His presentation will address the latest treatment options, emerging therapies, the role of clinical trials and quality of life considerations. A question-and-answer period will follow.

"Dr. Cortes will discuss the promising advances in CML treatment, and provide guidance on the importance of monitoring CML treatment and progress," says Robin Kornhaber, M.S.W., The Leukemia & Lymphoma Society's senior vice president of patient services.

The program is approved for 1.0 Continuing Education Unit for nurses and social workers upon verification of completion.


Registrants will receive an information packet and toll-free dial-in number within 48 hours of signing up. Participants can register online through or by phone at (866) 992-9950 ext. 302.

About Chronic Myelogenous Leukemia

CML is called by several names, including chronic granulocytic, chronic myelocytic or chronic myeloid leukemia. CML results from a change to the DNA of a stem cell in the marrow. Scientists do not yet understand what produces this change in the DNA, which is not present at birth.

The stem cell's changed DNA gives the malignant (cancerous) cell a growth and survival advantage over a normal stem cell. The resulting uncontrolled growth of white cells, if left untreated, will lead to a massive increase in their concentration in the blood. CML does not completely interfere with the development of mature red cells, white cells and platelets; these cells can generally continue to function normally. This is an important distinction from acute leukemia and accounts for the less severe early course of chronic leukemias.

About 4,570 people in the United States will learn they have CML in 2007 in the United States. About 21,501 people in the United States are living with CML. There will be an estimated 490 deaths from CML this year.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit or call the Society's Information Resource Center (IRC), a call center staffed by master's level oncology social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

CONTACT: Andrea Greif

(914) 821-8958

SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. GLEEVEC - An Oral treatment for leukemia
3. Cyclosporin A Treats Leukemia Complications
4. Aspirin Lowers Leukemia Risk
5. Skin Allergies Found To Increase The Risk Of Leukemia
6. Night Light Found To Increase The Risk Of Leukemia
7. Treating Leukemia With Natural Cells
8. Exposure to EMF may cause leukemia
9. A new vaccine for leukemia
10. Leukemia pill shows promise against stomach cancer
11. Hope for Chemo-Resistant Leukemia Patients
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: